Next 10 |
home / stock / ivbxf / ivbxf news
2024-07-10 14:06:41 ET Summary Context Therapeutics Inc.'s acquisition of CT-95, targeting MSLN expressing solid tumors, brings another shot on goal for its pipeline of T cell engagers. CTIM-76 is another T cell engager in the pipeline; however, it is being developed to go after o...
2024-06-01 14:44:45 ET More on etc. ARKK - Risky Does Not Equal Reward Canadian Tire Offers A Good Earnings Yield Despite Temporary Slowdown DAPP: Crypto Stocks Lose Some Luster In 2024 As New ETFs Capture The Spotlight Delta summer demand 'quite healthy' - C...
2024-05-31 08:59:26 ET More on Akeso, Merck, etc. Merck Stock: Still Discounted To Graham P/E Merck & Co., Inc. (MRK) BofA Securities 2024 Health Care Conference (Transcript) Merck: The Worst Has Been Avoided (Rating Upgrade) Dividend Roundup: Meta Platfo...
2024-05-26 02:45:00 ET Summary Jiangsu Hengrui Medicine out-licenses global rights for its GLP-1 candidates to US startup Hercules in a deal worth up to $6 billion. Shanghai Degron Therapeutics partners with Takeda to identify multiple targets in oncology, neuroscience, and inflam...
2024-05-21 10:29:09 ET More on Weight Loss Drugs Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead Genetics may determine who responds well to Wegovy: report One in eight U.S. adults admits to GLP-1 usage as public aware...
2024-05-12 03:45:00 ET Summary Hangzhou Sciwind Biosciences out-licenses South Korean rights for ecnoglutide injection to HK inno.N Corporation for up to $56 million. Beijing's Sino Biological completes its $48 million acquisition of SignalChem Biotech, adding enzyme production ex...
2024-05-09 12:40:14 ET More on Eli Lilly Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety Eli Lilly: Don't Overpay For Miracle Drugs Eli Lilly Alzheimer’s therapy set for June FDA...
2024-03-24 07:15:00 ET Summary Shanghai WuXi Biologics (HK: 2269) has broken ground on a $1.4 billion facility in Singapore, the first CRDMO to offer end-to-end biologics research, development and manufacturing in the city-state. Novo Nordisk announced plans to invest $556 million...
2024-03-10 03:55:00 ET Summary Shenzhen EurekaBio closed a $40 million Series B+ funding to support the commercialization of its EuLV™ Lentiviral Vector Production System. Chengdu Maxvax Biotechnology raised $40 million in a Series C financing round to advance its portfolio...
2024-02-25 05:00:00 ET Summary AlphaGen Therapeutics and ArtBio, two targeted RLT companies, forged a far-reaching agreement to expand ArtBio’s market and develop new RLTs. Biocytogen Pharma signed an antibody evaluation/option agreement with Gilead Sciences, granting acces...